TB-500 (Thymosin Beta-4 / Ac-SDKP)
Overview
TB-500 refers to synthetic material based on Thymosin Beta-4 (Tβ4), a 43-amino-acid actin-sequestering protein present in essentially all mammalian tissues, and specifically to its acetylated active fragment Ac-SDKP (Acetyl-Ser-Asp-Lys-Pro). Tβ4 and its fragment are studied in preclinical regenerative research for wound healing, angiogenesis, cell migration, anti-inflammatory and cytoprotective effects. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 77591-33-4 (Ac-SDKP fragment) |
| Class | Actin-sequestering peptide / Thymosin Beta-4 fragment |
| Active fragment | Ac-Ser-Asp-Lys-Pro (Ac-SDKP) |
| Molecular formula (fragment) | C₂₀H₃₂N₄O₉ |
| Molecular weight (fragment) | 500.52 g/mol |
| Full Tβ4 (43 aa) | ≈ 4963 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Actin-sequestering peptide (Tβ4 / Ac-SDKP)
- Origin
- Thymosin Beta-4, endogenous 43-aa protein
- Research status
- Extensive preclinical; limited clinical
- Study routes
- SC, IM, IV, topical
- Half-life
- ≈ 2–6 h (fragment)
- Key feature
- Angiogenic and wound-healing peptide
Mechanism of Action
The defining biochemistry of Thymosin Beta-4 is that it binds monomeric (G-)actin in a 1:1 complex, acting as the cell’s main actin buffer and so regulating the assembly of the cytoskeleton that drives cell movement. On top of this actin role, Tβ4 and Ac-SDKP are studied for angiogenic, anti-inflammatory and cytoprotective signalling.
| Component | Research description |
|---|---|
| Primary target | G-actin — sequesters actin monomers (1:1) |
| Angiogenesis | Associated with VEGF, MMP-2/9 and endothelial-cell migration |
| Cell migration | Promotes chemotaxis of endothelial cells, keratinocytes and fibroblasts |
| Anti-apoptotic tone | PI3K/Akt activation; Bcl-2 up, Bax down in models |
| Anti-inflammatory tone | Reduced NF-κB activation; lower TNF-α and IL-1β |
| Cardioprotective signalling | Akt/eNOS activation in cardiomyocytes |
Tissue-specific effects reported in the literature (research context, not therapeutic claims):
| Tissue | Studied mechanism | Reported direction |
|---|---|---|
| Skin | Keratinocyte migration, granulation tissue | Accelerated wound closure in models |
| Cardiac muscle | Myocyte survival, reduced fibrosis | Improved post-injury function in models |
| Cornea | Epithelial migration, reduced inflammation | Enhanced corneal healing in models |
| Skeletal muscle | Satellite-cell activation, reduced fibrosis | Improved regeneration in models |
| Nervous system | Neurite outgrowth, oligodendrocyte differentiation | Neuroprotective effects in models |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 2–6 h (Ac-SDKP); ~12–24 h (full Tβ4) |
| Bioavailability (SC) | ≈ 30–50% (estimated) |
| Bioavailability (oral) | Poor (proteolytic degradation in the GI tract) |
| Protein binding | Moderate (actin binding provides a tissue reservoir) |
| Metabolism | Proteolytic degradation by aminopeptidases |
| Route of administration | SC, IM, IV, topical (research settings) |
| Elimination | Renal (peptide fragments) |
Research Evidence
Thymosin Beta-4 has a substantial preclinical literature and some early-stage clinical work. Representative models and their focus are named below; specific numerical outcomes are not restated here as claims.
| Model | Research focus | Reference |
|---|---|---|
| Mouse skin-wound models | Angiogenesis and wound healing | Malinda KM, et al. (1999) |
| Rat corneal-epithelial wound | Corneal healing and inflammation | Sosne G, et al. (2005) |
| Murine myocardial injury | Cardiomyocyte survival and function | Bock-Marquette I, et al. (2004) |
| Rodent CNS-injury models | Neuroprotection and repair | Tβ4 preclinical literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Accelerated wound closure and angiogenesis | mouse wound model | Malinda KM et al., 1999 |
| Improved post-injury cardiac function | murine myocardial infarction | Bock-Marquette I et al., 2004 |
| Enhanced corneal epithelial healing | rat cornea | Sosne G et al., 2005 |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 1–5 mg per injection, 1–2× per week, in study protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Reconstitution volume | 1–2 mL per vial |
| Final concentration | ≈ 5–10 mg/mL |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~7 days |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published observations from research studies, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Local tolerability | Mild injection-site reactions; occasional transient headache |
| Cytotoxicity | No cytotoxicity observed in cell assays |
| Genotoxicity | Negative in standard assays |
| Cardiovascular | No adverse cardiac effects reported in models |
| Immunogenicity | Low; anti-Tβ4 antibodies uncommon |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Freely soluble (> 50 mg/mL) |
| logP (octanol/water) | ≈ −3.1 (hydrophilic) |
| Isoelectric point (pI) | ≈ 4.8 (Ac-SDKP fragment) |
| pH (reconstituted) | 5.5–6.5 |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
The Ac-SDKP fragment is produced by Fmoc solid-phase peptide synthesis with N-terminal acetylation; full-length Thymosin Beta-4 is a longer 43-residue synthesis. Both are purified by preparative HPLC to research grade.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Rink amide MBHA resin |
| Coupling | HBTU / HOBt with DIPEA in DMF |
| N-terminal acetylation | Acetic anhydride / DIPEA (for Ac-SDKP) |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. Full-length Tβ4 is characterised as a longer peptide; the Ac-SDKP fragment is the active tetrapeptide.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, reversed-phase TFA/ACN gradient | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 501 Da (Ac-SDKP fragment) |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 501 Da (Ac-SDKP fragment) |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 501 Da (Ac-SDKP fragment)). Full-length Tβ4 is characterised as a longer peptide; the Ac-SDKP fragment is the active tetrapeptide.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: Full-length Tβ4 is characterised as a longer peptide; the Ac-SDKP fragment is the active tetrapeptide.
Selected References
- Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
- Sosne G, et al. Thymosin beta-4 promotes corneal wound healing and reduces inflammation. Experimental Eye Research, 2005.
- Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac survival and repair. Nature, 2004.
- Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin beta-4. (review literature).
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Ac-SDKP fragment or full-length Tβ4 available on request
- Research samples through to bulk, with worldwide delivery
Need TB-500 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
